Drug combinations that include Oseltamivir (Tamiflu) are currently being provided to patients infected with the novel coronavirus and SARS-CoV-2 are currently being treated with. The drug is known to inhibit the neuraminidase enzyme, the enzyme present on the viral surface.
According to the previous findings, it was being said that adding Oseltamivir to usual primary care for influenza-like illness (ILI) accelerates recovery by about 1 day in those with ILI, and longer in those with key risk factors as being reported in the ALICE study (a randomised controlled trial of clinical and cost effectiveness in primary care). The effect of this study did not appear to be influenced by influenza virus status as was being detected by polymerase chain reaction (PCR) results from nasopharyngeal swabs. The ALICE study conducted has set out a post-hoc exploratory analysis of the matter-of-fact whether Oseltamivir can be used to primary care for patients with ILI who have tested positive for coronavirus (not including SARS-CoV-2) is effective in reducing time to recover or not.
Because of its noteworthy effect on influenza and being sold over the local dispensaries, Oseltamivir is not only present in common household medication, but also it is a common antiviral drug in essential clinics. Therefore, treatment for Covid-19 using Oseltamivir can be effective as it is family oriented .However, if the treatment effectiveness is not upto the extent, the use of Oseltamivir must be stopped, which will prevent other treatments and multiple adverse drug reactions, such as nausea, vomiting, epilepsy, elevated liver enzymes, and arrhythmias. Subsequently, the investigation of the antiviral impact of Oseltamivir against SARS-CoV-2 could positively affect the treatment of COVID-19.
Moreover, the use of Oseltamivir was also been reported during the COVID-19 epidemic in China, either with or without antibiotics and corticosteroids. Two case studies have stated the use of Oseltamivir (Tamiflu) in patients hospitalized with confirmed COVID-19 in China. Clinical trials of Oseltamivir as a combination drug therapy along with chloroquine and favipiravir a nucleoside analog has shown an EC50 of 61.88 μM against SARS-CoV-2 and CC50 >400 μ i.e. low toxicity levels.
However, according to JAMA publication, out of the 138 patients infected with COVID-19 who were being admitted to the hospital at an interval time gap of 7 days from the onset of symptoms, 124 patients received Oseltamivir. The dosage of Oseltamivir was adjusted based on the seriousness of the disease, and was not being reported. Thus, Oseltamivir in combination with other medications can prove to be a success as it is being currently studied in clinical trials for COVID-19.